0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV-74.42%PremiumDec 20, 2024Expiry Date1.28Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.15Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Renovaro Stock Discussion
keeping my eyes on this one
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
RenovaroCube (NASDAQ: RENB), a leader in AI-driven cancer diagnostics, presented groundbreaking research at the Molecular Analysis for Precision Oncology Congress on October 16, 2024. The study explores the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) from blood plasma to detect copy number alterations (CNAs) in lung cancer patients.
Key findi...
Globe Newswire 17-Sep-2024 9:00 AM
No comment yet